

Prescribing tip for information

Fentanyl transdermal patches in opioid-naive patients

MHRA Drug Safety Update (Sept 2020)

Fentanyl transdermal patches should not be started in opioid-naïve patients for non-cancer pain

This is now reflected in the Patient Information leaflet (PIL):

Warnings and precautions

Matrifen can have life-threatening side effects in people who are not already regularly using
prescribed opioid medicines.

Rationale¹:

- Serious harm and fatalities have been reported in patients treated with fentanyl patches
- Respiratory depression has been reported in opioid naïve and opioid experienced patients treated with fentanyl (MHRA Yellow card reporting)
- There is also significant risk with too rapid an escalation of dose, even in long-term opioid users
- 12 microgram/hour fentanyl patch equates to daily doses of oral morphine of up to 45mg a day¹

Alternatives to fentanyl:

- If pharmacological analgesia is indicated, then other analgesics (including other opioid analgesics) should be used for non-cancer pain before the use of fentanyl
- It is unusual for any analgesic, including strong analgesics like opioids, to completely eliminate chronic pain. The focus of treatment should be on reducing a person's pain with a view to improving their quality of life²
- New NICE <u>chronic pain guidance</u> states that opioid analgesics should **not** be initiated to manage primary chronic pain³
- Consider social prescribing options, exercise, acupuncture, and psychological therapies (ACT/CBT)³

Other relevant warnings:

MHRA/CHM advice: Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression (March 2020)

MHRA/CHM advice: Opioids: risk of dependence and addiction (September 2020)

MHRA/CHM advice: Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children (October 2018)

References:

¹ MHRA Drug Safety Alert. <u>https://www.gov.uk/drug-safety-update/transdermal-fentanyl-patches-for-non-cancer-pain-do-not-use-in-opioid-naive-patients</u>. September 2020

²NICE. <u>https://www.nice.org.uk/advice/ktt21/chapter/Key-points</u>. September 2019

³NICE Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. <u>https://www.nice.org.uk/guidance/ng193</u>. April 2021

To contact the Medicines Optimisation Team please phone 01772 214302